Results From the REGENCY Trial Assessing Efficacy and Safety of Obinutuzumab in Active Lupus Nephritis

7 Feb 2025 2:45 p.m. 3:15 p.m.
BradRovin Oral Abstract Presenter United StatesThe Ohio State University